MDM4 and cancer: Recently, Bernal et al. [69] showed in both in vitro and in vivo experiments that a “stabilized alpha-helix” of p53 peptide, SAH-p53-8, preferentially inhibits the binding of p53 with MdmX and reduces cancer cell viability, thereby overcomes MdmX-mediated cancer resistance.